The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine, offering end-to-end supply chain management to ensure integrity and viability of temperature-sensitive products. Proprietary assets including the Cryoportal logistics platform, first-to-market ISO 21973 certification, and the newly launched IntegriCell cryopreservation service create switching costs and enable premium pricing.
Cyborg Score Rationale
Q3 2025 revenue of $44.2M grew 15% year-over-year, with commercial cell & gene therapy revenue growing 36% to $8.3M and Life Sciences Services revenue rising 16%. Q3 2025 marked an inflection point with adjusted EBITDA loss narrowing to $600K and positive operating cash flow of $2.2M, with gross margins expanding to 48.2%.
Top Insights
Dominant market position supporting 745 clinical trials and 19 commercial cell & gene therapies with diversified revenue streams across Life Sciences Services and Products segments
IntegriCell cryopreservation service targets 60% gross margins and addresses critical industry bottleneck of standardized starting material for therapy developers
Trading at 0.29x EV/Revenue with $421M net cash position, representing asymmetric risk/reward in market growing 20-25% annually
Strategic CRYOPDP divestiture to DHL completed; company now pure-play in high-margin cell & gene therapy logistics with path to profitability by end-2025/early-2026
Named Competitors
Integrated Logistics Solutions — Large general logistics providers offering specialized cold-chain services
Biotech Manufacturing Services — Cell therapy manufacturing and logistics support providers
Regional Cold-Chain Operators — Niche players in specialized cryogenic logistics and storage
Recent Developments
(February 2026) Cryoport to report Q4 2025 earnings on March 3, 2026; analyst consensus raised to 'Moderate Buy' with average 12-month price target of $12.83
(October 2025) ISO 21973:2020 certification achieved by Cryoport Systems for transport of human cells for therapeutic use, strengthening traceability and chain-of-custody safeguards
(October 2025) Launched MVE Fusion 800 Series, a lab-sized self-sustaining cryogenic freezer for space-constrained environments at -150°C with 32-inch width
Open the full interactive Cryoport, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.